Gesynta Pharma's Endometriosis Trial Progresses
Analysis based on 8 articles · First reported Jun 17, 2026 · Last updated Jun 17, 2026
The positive progress in Gesynta Pharma's Phase 2 clinical trial for vipoglanstat could lead to increased investor confidence in the company and potentially attract future funding. This advancement in a non-hormonal, non-opioid treatment for endometriosis addresses a significant unmet medical need, which could translate into substantial market opportunities if successful.
Gesynta Pharma, a Swedish clinical-stage pharmaceutical company, announced that its Phase 2 clinical proof-of-concept trial (NOVA) for vipoglanstat has randomized 50% of its target of 190 patients. This milestone was achieved ahead of schedule. Vipoglanstat is a novel, non-hormonal, non-opioid drug candidate for the treatment of endometriosis, a chronic inflammatory disease affecting over 10% of women of reproductive age. The NOVA trial is evaluating the efficacy and safety of two dose levels of vipoglanstat across Europe, with top-line results expected in 2027. The rapid patient recruitment reflects strong participation from clinical sites and significant interest from eligible participants, underscoring the urgent need for better treatments for endometriosis. Gesynta Pharma's shareholders include Hadean Ventures, Industrifonden, Innovestor Life Science, Linc, HealthCap, and XGen Venture.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard